Cepheid (CPHD) GeneXpert TB Test in India
“A Deadly Misdiagnosis” by Michael Specter An interesting article in the November 15 New Yorker on the Tuberculosis epidemic in India stresses the need for more accurate diagnostic tests and how the Cepheid TB assay can save lives. The author reports on the complexity and economics...
Biomarkers and Blood Screening Tests: GenProbe (GPRO) and Genzyme(GENZ)
Here are some relevant news in areas that we previously covered: Biomarkers Genzyme (GENZ) licensed a lung cancer test under development to Roche and can target a patient’s response to their Tarceva cancer drug. The goal is a test for epidermal growth- factor receptor (EGFR) mutations...
Market Ignores Bad News, Rallies on Retail Outlook
The market overcame bad news for Ireland and European debt, insider trading investigations , Korean crisis and a weak housing market for an S&P rally of 1.49%. NASDAQ is doing even better up 1.93% boosted by Apple (AAPL $315) up 2% and Amazon(AMZN $177) up 5.5%. Most retail stocks lead the...
Rayno Life Science Portfolio: Regeneron(REGN)up 14% on Eye Drug Phase 3 Results
Regeneron(REGN $28) stock soared today on two parallel Phase 3 studies with patients who had neovascular age related macular degeneration(wet AMD), the VEGF Trap Eye drug successfully met the endpoint compared to the current standard of care, ranibizumab dosed every month.Regeneron and its...
Rayno Life Science Portfolio:Exelixis (EXEL) and Neogen (NEOG) Soar
Exelixis (EXEL) stock was up over 30% today to $6.14 on positive data from two experimental cancer drugs for prostate and ovarian cancer. The XL 184 drug showed promising results with castration-resistant prostate cancer (CRPC) achieving either partial or complete remission in 19/20 prostate...
